Cargando…
Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity
Severe cold agglutinin disease with hemodynamic compromise requires rapid stabilization of the autoimmune hemolytic anemia as a bridge to the immunosuppressive effect of rituximab. Herein, we describe eculizumab treatment of severe complement-mediated hemolysis in a patient whose hemodynamic status...
Autores principales: | Shapiro, Roman, Chin-Yee, Ian, Lam, Selay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641479/ https://www.ncbi.nlm.nih.gov/pubmed/26576277 http://dx.doi.org/10.1002/ccr3.399 |
Ejemplares similares
-
Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab
por: Dawudi, Yachar, et al.
Publicado: (2022) -
Cold Agglutinin Disease
por: Gabbard, Amy P., et al.
Publicado: (2020) -
Mycoplasma pneumonia with persistent lymphadenopathy and severe cold agglutinin haemolysis
por: Shah, Mit, et al.
Publicado: (2016) -
Pembrolizumab-Induced Cold Agglutinin Disease
por: Atiq, Osman, et al.
Publicado: (2020) -
Necrosis secondary to cold agglutinin disease
por: Nakagawa, Hiroaki, et al.
Publicado: (2022)